[
  {
    "date": "2023-12-31",
    "symbol": "TLSA",
    "period": "FY",
    "cashandcashequivalents": 1183000,
    "prepaymentsandotherreceivablescurrent": 223000,
    "taxationreceivable": 3793000,
    "amountsreceivablerelatedpartytransactions": 2138000,
    "currentassets": 7337000,
    "propertyplantandequipment": 10000,
    "rightofuseassets": 283000,
    "investmentsinrelatedparty": 4554000,
    "noncurrentassets": 4847000,
    "assets": 12184000,
    "tradeandothercurrentpayables": 6387000,
    "currentleaseliabilities": 138000,
    "othercurrentliabilities": 14000,
    "currentliabilities": 6539000,
    "noncurrentleaseliabilities": 109000,
    "liabilities": 6648000,
    "issuedcapital": 103000,
    "sharepremium": 16492000,
    "reserveofsharebasedpayments": 6905000,
    "otherreserves": 118697000,
    "treasuryshares": 1574000,
    "sharestobeissuedreserve": 225000,
    "reserveofexchangedifferencesontranslation": -1636000,
    "retainedearnings": -133676000,
    "equity": 5536000,
    "equityandliabilities": 12184000,
    "issuanceofsharecapital": 103087744,
    "sharecapitaloutstanding": 103087744,
    "researchanddevelopmentexpense": 8113000,
    "otherexpensebyfunction": 9871000,
    "operatingexpense": 17984000,
    "profitlossfromoperatingactivities": -17984000,
    "financeincomecost": 1144000,
    "gainslossesondisposalsofinvestments": -402000,
    "othergainslosses": 742000,
    "profitlossbeforetax": -17242000,
    "incometaxscredit": 449000,
    "profitloss": -17691000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 1492000,
    "comprehensiveincome": -16199000,
    "basicearningslosspershare": -0.17,
    "dilutedearningslosspershare": -0.17,
    "optionsforfeitedcancelled": 103,
    "increasedecreasethroughexerciseofoptions": -19000,
    "shareissuerelatedcost": 1000,
    "warrantsexercisedintheyear": 573000,
    "warrantsforfeitedintheyear": -259000,
    "buybackoftreasuryshares": -254000,
    "sharestobeissuedinlieuofdirectorsfeesandcashbonus": 225000,
    "sharebasedpaymentoptions": 1773000,
    "increasedecreasethroughtransactionswithowners": 1000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation1": 1492000,
    "sharesissuedinlieuoffees": 425000,
    "adjustmentsforsharebasedpaymentswarrants": 1773000,
    "optionsforfeitedduringtheyear": 39000,
    "fvlossoninvestment": 402000,
    "bonustobesettledinequity": 100000,
    "adjustmentsfordepreciationexpense": 7000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -1519000,
    "depreciationofrightofuseasset": 89000,
    "interestreceivedfromloan": 1150000,
    "netincreaseinrelatedpartyreceivables": 1524000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 80000,
    "adjustmentsforincreasedecreaseinotherliabilities": -138000,
    "cashflowsfromusedinoperatingactivities": -15698000,
    "investmentinrelatedparty": 1000000,
    "purchaseoftreasuryamount": 253000,
    "cashflowsfromusedininvestingactivities": -1253000,
    "fundraisingcost": 24000,
    "proceedsfromissuanceofoptions": 135000,
    "repaymentofleasingliabilities": -119000,
    "cashflowsfromusedinfinancingactivities": 40000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -16911000,
    "effectofexchangeratechangesoncashandcashequivalents": -28000,
    "investmentinrelatedpartytextblock": "19. INVESTMENT IN RELATED PARTY             Year ended December 31,       Group     2023      2022             $000      $000       Investment in Accustem Sciences Inc      1,806       2,675       Movement in fair value      (969)      (869)             837       1,806",
    "descriptionofaccountingpolicyforbasisofpreparationtextblock": "Basis of preparation",
    "descriptionofaccountingpolicyforgoingconcern": "Going Concern",
    "descriptionofaccountingpolicyfornewandrevisedstandardstextblock": "New and Revised Standards",
    "descriptionofaccountingpolicyforbasisofconsolidation": "Basis of consolidation",
    "descriptionofaccountingpolicyforlicensefees": "<p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify\"><b>License fees</b></p><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in\">Payments made which providethe right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. “Licensefees expenses” are recognized as incurred.</p>",
    "descriptionofaccountingpolicyforwarrantstextblock": "Warrants",
    "descriptionofaccountingpolicyforsublicenseincometextblock": "Sub license income",
    "disclosureofestimatedusefullivesforthecurrentperiodandthecomparativeperiodtextblock": "The estimated useful livesfor the current period and the comparative period are as follows.",
    "disclosureofdetailedinformationaboutoperatingloss": "The Group’s operatinglosses are stated after charging/(crediting) the following:",
    "disclosureofshareoptionsweregrantedtodirectortextblock": "The following share optionswere granted to directors in the following periods:",
    "disclosureofdetailedinformationaboutofearningspersharetabletextblock": "Basic loss per share is calculatedby dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during theyear.",
    "disclosureofdetailedinformationaboutotherreceivablestabletextblock": "$000         Year ended December 31, 2023                          2023                   2022           Security deposits receivable              121                   130           Prepayments              102                   170           Taxation Receivable              3,793                   4,246                          4,016                   4,546",
    "disclosuresharecapitalarisingforshareexchangetextblock": "The share capital arising on the share forshare exchange has been presented as share capital in the comparative period.",
    "scheduleofoutstandingfairvaluechargeoftheshareoptioninstrumentstabletextblock": "Share options outstandingat the end of the year have the following expiry dates and exercise prices:",
    "scheduleofmodelinputsforoptionsgrantedundertheblackscholesvaluationmodeltabletextblock": "The model inputs for optionsgranted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:",
    "scheduleoffinancialliabilitiesbasedoncontractualundiscountedpaymentstabletextblock": "The table below summarizesthe maturity profile of the Group’s financial liabilities based on contractual undiscounted payments:",
    "scheduleofmeasurementofthefinancialinstrumentstextblock": "This analysis assumesthat all other variables remain constant.",
    "scheduleoftradeandotherpayablestabletextblock": "Year ended December 31,       Group     2023      2022             $000      $000       Trade payables      4,137       4,962       Accruals      2,250       1,570              6,387       6,532",
    "disclosureofquantitativeinformationaboutrightofuseassetstabletextblock": "Any leases that have a term shorter than 12 months the Group has appliedthe exemption allowed by paragraph 5a in IFRS16 in respect of short – term leases.",
    "disclosureoffutureminimumleasepayments": "The lease liabilities aresecured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:",
    "estimatedusefullives": "P5Y",
    "rightofuseassetdescription": "Economic life of contractual relationship",
    "licensefee": 563000,
    "depreciationexpense": 7000,
    "depreciationrightofuseassets": 89000,
    "foreignexchangegainlosses": 1519000,
    "directorsremunerationexpense": 929000,
    "wagesandsalaries": 1777000,
    "socialsecuritycontributions": 136000,
    "recruitmentfees": 24000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1730000,
    "employeebenefitsexpense": 4596000,
    "researchanddevelopment": 3000,
    "corporateandadministration": 6000,
    "averagemonthlynumberofemployeesincludingdirectorsemployedbygroup": 9000,
    "directorsfees": 717000,
    "bonus": 100000,
    "sharebasedpayments": 562000,
    "numberofshareoptionsweregrantedtodirectors": 75000,
    "interestexpenseonborrowings": 1154000,
    "financeincome": 1154000,
    "interestexpenseonleaseliabilities": 10000,
    "financialassetsatfairvaluethroughprofitorloss": 402000,
    "financeexpense": 412000,
    "netfinanceexpenserecognizedinstatementofcomprehensiveincome": 742000,
    "currenttaxexpenseincome": 449000,
    "incometaxexpensecontinuingoperation": 449000,
    "otherlossbeforetaxation": -17242000,
    "incometaxreconciliationlosschargedatstandardrateofcorporationtax": -4055000,
    "movementinunrecogniseddeferredtax": 3194000,
    "incometaxreconciliationexpensesnotdeductiblefortaxation": 3961000,
    "adjustmentsduetopriorperiod": 449000,
    "incomenottaxablefortaxpurposes": -3113000,
    "currenttaxother": 13000,
    "incometaxexpensecontinuingoperations": 449000,
    "taxrateeffectoftaxlosses": 0.2352,
    "weightedaverageshares": 102471016,
    "basiclosspersharecentspershare": -17.3,
    "securitydepositsreceivable": 121000,
    "prepayments": 102000,
    "otherreceivables": 4016000,
    "sharecapitalshares": 103087744,
    "sharecapitalvalueat31december2021": 103000,
    "sharepremiumending": 16492000,
    "mergerreserveending": 118697000,
    "nominalvaluesharesissuedinlieuoffees": 0.0001,
    "sharecapitalsharesissuedinlieuoffees": 450000,
    "sharecapitalvaluesharesissuedinlieuoffees": 1000,
    "sharepremiumsharesissuedinlieuoffees": 300000,
    "nominalvaluewarrantsexercised": 0.0001,
    "sharecapitalshareswarrantsexercised": 337501,
    "sharepremiumwarrantsexercised": 573000,
    "nominalvalueissuanceofstockatm": 0.0001,
    "sharecapitalsharesissuanceofstockatm": 27629,
    "sharepremiumissuanceofstockatm": 23000,
    "weightedaverageexercisepriceoutstanding": 62,
    "optionsoutstanding": 6621,
    "weightedaverageexercisepriceforfeitedcancelled": -44,
    "weightedaverageexercisepriceexercisable": 60,
    "optionsexercisable": 2829,
    "expirydate": "26 June 2024",
    "exerciseshareprice": 0.47,
    "shareoptions": 1831,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 73,
    "numberofshareoptionsoutstanding": 4268,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 61,
    "numberofshareoptionsgranted": 1753,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 57,
    "numberofshareoptionsforfeited": 60,
    "outstandingexercised": -438000,
    "outstandingexpired": -259000,
    "tradeandotherpayables": 2223000,
    "leaseliabilities": 34000,
    "financialinstrumentsnet": 2354000,
    "profitorlossandequitystrengthening": 467000,
    "profitorlossandequityweakening": -467000,
    "movementpercentagestrengthening": 0.05,
    "movementpercentageweakening": 0.05,
    "tradeandotherpayablestotradesuppliers": 4137000,
    "accrualsclassifiedascurrent": 2250000,
    "adjustmentsforgainslossesonfairvalueadjustmentinvestmentproperty": 1806000,
    "impairmentlossonfinancialassets": -969000,
    "impairmentlossrecognisedinprofitorlossinvestmentproperty": 837000,
    "rightofuseassetbeginning": 372000,
    "rightofuseassetsdepreciation": -104000,
    "exchangedifferencesrightofuseassets": 15000,
    "rightofuseassetstotal": 283000,
    "leaseliabilitiesbeginning": 365000,
    "leaseliabilitiesinterestexpense": 10000,
    "leaseliabilitiesleasepayments": -119000,
    "exchangedifferences": -9000,
    "leaseliabilitiestotal": 247000,
    "othernoncurrentliabilities": 247000,
    "leasepayments": 148000,
    "financecharges": -10000,
    "netpresentvalues": 138000,
    "accumulatedloss": 134000,
    "cashsurplus": "P12M",
    "numberofsegment": 1,
    "insurancefinanceincomeexpenses": 804000,
    "otherlongtermbenefits": 13200000,
    "postemploymentbenefitexpensedefinedcontributionplans": 56000,
    "maximumpercentageofsurrenderablelosses": 0.145,
    "termofresearchanddevelopmenttaxreliefclaims": "P2Y",
    "taxeffectoftaxlosses": 18137000,
    "parvaluepershare": 0.001,
    "numberofsharesissued1": 103087744,
    "treasuryshares1": 1573510,
    "outstandingfairvaluecharges": 2602000,
    "expensefromsharebasedpaymenttransactionswithpartiesotherthanemployees": 703000,
    "expectedtermofawards": "P4Y",
    "expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 1019000,
    "chargeofforfeitures": 57000,
    "sharesprice": 63,
    "acquiredshares": 2100000,
    "numberofsharesissuedandfullypaid": 254000,
    "interestamount": 75000000,
    "shorttermloanfacility1": 0.16,
    "payrollandrentcharged": 416000,
    "servicesagreementamount": 6000,
    "proportionofownershipinterestinsubsidiary": 0.2,
    "principalamount": 2000000,
    "interestincomeonimpairedfinancialassetsaccrued": 1150000,
    "numberofsharesissued": 2100000,
    "servicesexpense": 1324000,
    "developmentmilestones": 1000000,
    "accruedofdiligenceobligations": 750000,
    "milestonepayments": 300000,
    "commercialsaleofaproduct": 3000000,
    "entityregistrantname": "Tiziana Life Sciences Ltd",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 103087744,
    "amendmentflag": "false",
    "entitycentralindexkey": 1723069,
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityincorporationstatecountrycode": "D0",
    "entityaddressaddressline1": "Clarendon House",
    "entityaddressaddressline2": "2 Church Street,",
    "entityaddresscityortown": "Hamilton HM",
    "entityaddresspostalzipcode": 11,
    "entityaddresscountry": "BM",
    "contactpersonnelname": "Keeren Shah",
    "cityareacode": 44,
    "localphonenumber": "20 7495 2379",
    "entityinteractivedatacurrent": "No",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 2814,
    "auditorname": "PKF Littlejohn LLP",
    "auditorlocation": "London, England",
    "documentregistrationstatement": "false",
    "entityfilenumber": "000-00000"
  },
  {
    "date": "2022-12-31",
    "symbol": "TLSA",
    "period": "FY",
    "cashandcashequivalents": 18122000,
    "prepaymentsandotherreceivablescurrent": 300000,
    "taxationreceivable": 4246000,
    "amountsreceivablerelatedpartytransactions": 1614000,
    "currentassets": 24282000,
    "propertyplantandequipment": 17000,
    "rightofuseassets": 372000,
    "tradeandothercurrentreceivablesduefromrelatedparties": 1806000,
    "noncurrentassets": 2195000,
    "assets": 26477000,
    "accountspayableandaccruedexpensescurrent": 6532000,
    "currentleaseliabilities": 122000,
    "otherliabilities": 9000,
    "currentliabilities": 6663000,
    "noncurrentleaseliabilities": 243000,
    "liabilities": 6906000,
    "issuedcapital": 102000,
    "sharepremium": 15596000,
    "reserveofsharebasedpayments": 5190000,
    "sharebasedpaymentreservewarrants": 697000,
    "otherreserves": 118697000,
    "treasuryshares": 1320000,
    "reserveofexchangedifferencesontranslation": -3128000,
    "retainedearnings": -116263000,
    "equity": -3128000,
    "equityandliabilities": 26477000,
    "issuanceofsharecapital": 102272614,
    "sharecapitaloutstanding": 102272614,
    "researchanddevelopmentexpense": 12955000,
    "otheroperatingincomeexpense": -1631000,
    "totaloperatingexpenses": -14586000,
    "profitlossfromoperatingactivities": -14586000,
    "financeincomecost": -7000,
    "otherincomelosses": -804000,
    "othergainslosses": -811000,
    "profitlossbeforetax": -15397000,
    "profitloss": -15397000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -3582000,
    "comprehensiveincome": -18979000,
    "basicearningslosspershare": -0.15,
    "dilutedearningslosspershare": -0.15,
    "issueofequity": -1320000,
    "optionsforfeitedcancelled": 6910000,
    "increasedecreasethroughexerciseofoptions": 7197000,
    "sharebasedpaymentoptions": 1811000,
    "increasedecreasethroughtransactionswithowners": -1410000,
    "profitloss1": -15397000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation1": -3582000,
    "comprehensiveincome1": -18979000,
    "adjustmentsforforfeitureofoptions": 1811000,
    "fvlossoninvestment": 869000,
    "lossondisposalofasset": 129000,
    "adjustmentsfordepreciationexpense": 1000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 3183000,
    "optionsforfeitedduringtheyear": 3221000,
    "depreciationofrightofuseasset": 50000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -490000,
    "netincreaseinrelatedpartyreceivables": 1158000,
    "netincreaseinrelatedpartypayables": -1355000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 1002000,
    "adjustmentsforincreasedecreaseinotherliabilities": 347000,
    "cashflowsfromusedinoperatingactivities": -19615000,
    "investmentinrelatedparty": 2676000,
    "purchaseoftreasuryamount": 1320000,
    "cashflowsfromusedininvestingactivities": -3996000,
    "repaymentofleasingliabilities": -55000,
    "cashflowsfromusedinfinancingactivities": -55000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -23666000,
    "effectofexchangeratechangesoncashandcashequivalents": -398000,
    "disclosureofgeneralinformationaboutfinancialstatementsandorganization": "1. GENERAL INFORMATION ",
    "descriptionofsegmentreportingexplanatory": "6. SEGMENTAL REPORTING ",
    "disclosureofreservestextblock": "15. RESERVES ",
    "investmentinrelatedpartytextblock": "19. INVESTMENT IN RELATED PARTY ",
    "thedisclosureofbasisofpreparation": "Basis of preparation ",
    "descriptionofaccountingpolicyforgoingconcern": "Going Concern ",
    "descriptionofaccountingpolicyforbasisofconsolidation": "Basis of consolidation ",
    "descriptionofaccountingpolicyforlicensefees": "License fees ",
    "warrantspolicytextblock": "Warrants ",
    "sublicenseincomepolicytextblock": "Sub license income ",
    "disclosureofdetailedinformationaboutestimatedusefullives": "      Fixtures and fittings    5 years      IT and equipment    3 years      Right of use asset    Economic life of contractual relationship   ",
    "disclosureofdetailedinformationaboutoperatingloss": "            Year Ended December 31,             2022 $’000      2021 $’000      2020 $’000       License fee      -       (1,047)      706       Realization bonus      -       855       13,503       Foreign exchange gain related to the realization bonus      -       -       (289)      Depreciation of Property, plant and equipment      1       8       5       Depreciation (Right-of-use asset)      50       133       86       Foreign exchange (gains)/losses      (3,183)      (1,899)      239    ",
    "disclosureofshareoptionsweregrantedtodirectorstextblock": "            Year ended December 31,             2022      2021      2020             Number of options      Number of options      Number of options                                   G. Cerrone      -       -       1,800,000       K. Shailubhai      -       -       -       L. Zanbeletti      -       -       -       W.Simon      -       -       250,000       J. Brancaccio      -       -       250,000       T Adams      -       3,500,000       -              -       3,500,000       2,300,000    ",
    "disclosureofdetailedinformationaboutofearningspersharetabletextblock": "            Year ended December 31,             2022      2021      2020                                   (Loss) attributable to equity holders of the company ($000)      (15,397)      (23,417)      (26,131)      Weighted average number of ordinary shares in issue      101,526,389       97,932,055       97,306,144       Basic loss per share (cents per share)      (15.2)      (23.9)      (26.9)   ",
    "disclosureofdetailedinformationaboutotherreceivablestabletextblock": "      $000     Year    ended December 31,              2022      2021                            VAT Receivable      -       80       Security deposits receivable      130       35       Prepayments      170       1,186              300       1,301    ",
    "scheduleofoutstandingfairvaluechargeoftheshareoptioninstrumentstabletextblock": "      Grant Date     Expiry Date     Exercise Price      Share Options  at 31 December     2022    (‘000)       26 June 2014     26 June 2024     $0.47       1,831       30 April 2018     30 April 2028     $1.10       500       6 May 2020     5 May 2028     $0.47       12,393       23 July 2020     26 July 2030     $2.11       100       25 August 2020     24 August 2030     $1.98       500       Total                    15,324    ",
    "scheduleofequityincentiveplantabletextblock": "            2022             Weighted                    Average exercise price    (cents)      Options (’000)                            Outstanding at 1 January      -       -       Granted      69       2,575       Forfeited/Cancelled      -       -       Exercised      -       -                              Outstanding at 31 December      69       2,575                              Exercisable at 31 December      -       -    ",
    "scheduleofestimatedthefairvalueofwarrantsusingtextblock": "            2022                                              $000      2021                                              $000      2020                                              $000                                   Outstanding at 1 January      697       697       2,418       Granted      -       -       324       Transfer to share premium on exercise of warrants      -       -       2,045)                                     Outstanding at 31 December      697       697       697    ",
    "scheduleoffinancialliabilitiesbasedoncontractualundiscountedpaymentstabletextblock": "            2022       $000     Less than  3 months      3 to 12  months      Total       Trade payables      1,230       3,732       4,962       Lease liabilities      32       98       130       Related party payables      -       -       -       Total      1,262       3,830       5,092    ",
    "scheduleofmeasurementofthefinancialinstrumentstextblock": "                Profit    or loss and equity           December    31, 2022         Strengthening              Weakening           USD (5% movement)              415                   (415)                                                      ",
    "scheduleoftradeandotherpayablestabletextblock": "            Year ended December 31,       Group     2022      2021             $000      $000       Trade payables      4,962       4,406       Accruals      1,570       1,775              6,532       6,181   ",
    "disclosureofquantitativeinformationaboutrightofuseassetstabletextblock": "      Right-of-use assets     31 Dec 2022      31 Dec 2021             $000      $000       At 1 January 2022      448       357       Depreciation      (50)      (133)      Disposal of lease      -       (224       Exchange differences      (26)                     372       -    ",
    "disclosureoffutureminimumleasepayments": "            Minimum lease payment due             Within 1 year      1-2 years      2-5 years      Over 5 years      Total       Lease payments      139       139       104       -       382       Finance Charges      (9)      (6)      (2)      -       (17)      Net Present Values      130       133       102               365    ",
    "estimatedusefullives": 3,
    "rightofuseassetdescription": "Economic life of contractual relationship",
    "otherfinanceincome": 65000,
    "noncurrentfinancialassetsatfairvaluethroughprofitorlossmeasuredassuchinaccordancewithexemptionforreacquisitionofownequityinstruments": -869000,
    "depreciationexpense": 1000,
    "depreciationrightofuseassets": 50000,
    "foreignexchangegainlosses": -3183000,
    "directorsremunerationexpense": 554000,
    "wagesandsalaries": 2014000,
    "socialsecuritycontributions": 135000,
    "recruitmentfees": 197000,
    "expensefromsharebasedpaymenttransactionswithemployees": -1410000,
    "employeebenefitsexpense": 1242000,
    "researchanddevelopment": 3000,
    "corporateandadministration": 6000,
    "averagemonthlynumberofemployeesincludingdirectorsemployedbygroup": 9000,
    "directorsfees": 406000,
    "bonus": 148000,
    "salary": 379000,
    "sharebasedpayments": -1946000,
    "interestexpenseonleaseliabilities": 7000,
    "financeexpense": 7000,
    "netfinanceexpenserecognizedinstatementofcomprehensiveincome": 7000,
    "weightedaverageshares": 101526389,
    "basiclosspersharecentspershare": -15.2,
    "securitydepositsreceivable": 130000,
    "prepayments": 170000,
    "tradeandotherreceivables": 300000,
    "sharecapitalshares": 102272614000,
    "sharecapitalvalueat31december2021": 102000,
    "sharepremiumending": 15596000,
    "mergerreserveending": 118697000,
    "weightedaverageexercisepriceoutstanding": 49,
    "optionsoutstanding": 15324000,
    "weightedaverageexercisepriceforfeitedcancelled": 176,
    "weightedaverageexercisepriceexercisable": 48,
    "optionsexercisable": 6249000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 69,
    "numberofshareoptionsoutstanding": 2575000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 69,
    "numberofshareoptionsgranted": 2575000,
    "fairvalueoutstanding": 697000,
    "tradeandotherpayables": 4962000,
    "leaseliabilities1": 130000,
    "financialinstrumentsnet": 5092000,
    "profitorlossandequitystrengthening": 415000,
    "profitorlossandequityweakening": -415000,
    "movementpercentagestrengthening": 0.05,
    "movementpercentageweakening": 0.05,
    "tradeandotherpayablestotradesuppliers": 4962000,
    "accrualsclassifiedascurrent": 1570000,
    "tradeandothercurrentpayables": 6532000,
    "adjustmentsforgainslossesonfairvalueadjustmentinvestmentproperty": 2675000,
    "impairmentlossonfinancialassets": -869000,
    "impairmentlossrecognisedinprofitorlossinvestmentproperty": 1806000,
    "rightofuseassetbeginning": 448000,
    "rightofuseassetsdepreciation": -50000,
    "exchangedifferencesrightofuseassets": -26000,
    "rightofuseassetstotal": 372000,
    "leaseliabilitiesbeginning": 448000,
    "leaseliabilitiesinterestexpense": 6000,
    "leaseliabilitiesleasepayments": -61000,
    "exchangedifferences": -28000,
    "leaseliabilitiestotal": 365000,
    "leaseliabilities": 365000,
    "leasepayments": 382000,
    "financecharges": -17000,
    "netpresentvalues": 365000,
    "cashsurplus": 1000000,
    "numberofsegment": 1,
    "gabrielecerronesbonusdescription": "Gabriele Cerrone’s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.",
    "postemploymentbenefitexpensedefinedcontributionplans": 32,
    "maximumpercentageofsurrenderablelosses": 0.145,
    "termofresearchanddevelopmenttaxreliefclaims": 2,
    "taxeffectoftaxlosses": 15011000,
    "parvaluepershare": 0.001,
    "sharesinentityheldbyentityorbyitssubsidiariesorassociates": 1683544,
    "numberofsharesissued1": 102272614,
    "treasuryshares1": 1683544,
    "outstandingfairvaluecharges": 1176000,
    "expensefromsharebasedpaymenttransactionswithpartiesotherthanemployees": 3221000,
    "totalexpenses": 332000,
    "commonstockshares": -1337970,
    "dividendspaidothersharespershare": 0.001,
    "aggregatepurchaseprice": 2,
    "purchasesofgoodsrelatedpartytransactions": 2675940,
    "sharesprice": 1.35,
    "insurancefinanceincomeexpenses": 869000,
    "sharespurchases": 1683544,
    "interestamount": 75000,
    "shorttermloanfacility1": 0.16,
    "payrollandrentcharged": 72000,
    "servicesagreementamount": 125,
    "loansreceived": 1056,
    "otherequityinterest": 19000,
    "expenserecognisedduringperiodforbadanddoubtfuldebtsforrelatedpartytransaction": 295,
    "costofsalesroomoccupancyservices": 72000,
    "cashoutflowforleases": 55,
    "financialcommitmentsdescription": "(a)",
    "accruedofdiligenceobligations": 750000,
    "developmentmilestonesdescription": "(a)",
    "milestonepayments": 630000,
    "currentdebtinstrumentsissued": 1056,
    "entityregistrantname": "TizianaLife Sciences Ltd",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 102272614,
    "amendmentflag": "false",
    "entitycentralindexkey": 1723069,
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityincorporationstatecountrycode": "Bermuda",
    "entityaddressaddressline1": "Chief Financial Officer",
    "entityaddressaddressline2": "14-15 Conduit Street",
    "entityaddresscityortown": "London",
    "entityaddresspostalzipcode": "W1S 2XJ",
    "entityaddresscountry": "UnitedKingdom",
    "contactpersonnelname": "Keeren Shah",
    "cityareacode": 44,
    "localphonenumber": "20 7495 2379",
    "entityinteractivedatacurrent": "No",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 2814,
    "auditorname": "PKF Littlejohn LLP",
    "auditorlocation": "London, England",
    "documentregistrationstatement": "false",
    "entityfilenumber": "000-00000"
  },
  {
    "date": "2021-12-31",
    "symbol": "TLSA",
    "period": "FY",
    "cashandcashequivalents": 42186000,
    "prepaymentsandotherreceivablescurrent": 1301000,
    "taxationreceivable": 4736000,
    "amountsreceivablerelatedpartytransactions": 456000,
    "currentassets": 48679000,
    "propertyplantandequipment": 17000,
    "intangibleassetsotherthangoodwill": 130000,
    "noncurrentassets": 147000,
    "assets": 48826000,
    "accountspayableandaccruedexpensescurrent": 6181000,
    "amountspayablerelatedpartytransactions": 1355000,
    "otherliabilities": 10000,
    "currentliabilities": 7546000,
    "liabilities": 7546000,
    "issuedcapital": 102000,
    "sharepremium": 15596000,
    "reserveofsharebasedpayments": 13797000,
    "sharebasedpaymentreservewarrants": 697000,
    "otherreserves": 118697000,
    "reserveofexchangedifferencesontranslation": 454000,
    "retainedearnings": -108063000,
    "equity": 454000,
    "equityandliabilities": 48826000,
    "issuanceofsharecapital": 102272614,
    "sharecapitaloutstanding": 102272614,
    "researchanddevelopmentexpense": 13208000,
    "otheroperatingincomeexpense": -13311000,
    "realisationbonus": 855000,
    "totaloperatingexpenses": -27374000,
    "profitlossfromoperatingactivities": -27374000,
    "financeincomecost": -176000,
    "otherincome": 893000,
    "othergainslosses": 717000,
    "profitlossbeforetax": -26657000,
    "incometaxscredit": -3240000,
    "profitloss": -23417000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -4478000,
    "comprehensiveincome": -27895000,
    "basicanddilutedlosspershareattributabletocommonshareholders": -0.24,
    "issueofsharecapitalloanconversion": 761000,
    "sharestobeissuedinlieuofcashrealizationbonus": 855000,
    "sharebasedpaymentoptions": 5173000,
    "increasedecreasethroughtransactionswithowners": 6789000,
    "profitloss1": -23417000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation1": -4478000,
    "comprehensiveincome1": -27895000,
    "adjustmentsforinterestexpense": 163000,
    "adjustmentsforforfeitureofoptions": -5173000,
    "bonustobesettledinequity": 855000,
    "adjustmentsfordepreciationexpense": 8000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 1899000,
    "depreciationofrightofuseasset": 133000,
    "profitslossesondisposalofinvestmentsandchangesinvalueofinvestments": 28000,
    "proceedsfromsaleandcollectionoffinancereceivables": -152000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -1415000,
    "netincreaseinrelatedpartyreceivables": 88000,
    "netincreaseinrelatedpartypayables": -685000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 516000,
    "adjustmentsforincreasedecreaseinotherliabilities": -516000,
    "cashflowsfromusedinoperatingactivities": -21762000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 22000,
    "proceedsfromfinancelease": 152000,
    "cashflowsfromusedininvestingactivities": 130000,
    "proceedsfromissuanceofwarrant": 129000,
    "repaymentofleasingliabilities": -152000,
    "cashflowsfromusedinfinancingactivities": -23000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -21655000,
    "effectofexchangeratechangesoncashandcashequivalents": -1983000,
    "disclosureofgeneralinformationaboutfinancialstatementsandorganization": "1.GENERAL INFORMATION ",
    "descriptionofsegmentreportingexplanatory": "6.SEGMENTAL REPORTING ",
    "financeleasereceivabletextblock": "      14.    FINANCE LEASE RECEIVABLE   ",
    "convertibleinstrumentsclassifiedasequity": "18. CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY ",
    "disclosureofreservestextblock": "19.RESERVES ",
    "thedisclosureofbasisofpreparation": "Basisof preparation ",
    "descriptionofaccountingpolicyforgoingconcern": "GoingConcern ",
    "descriptionofaccountingpolicyforbasisofconsolidation": "Basisof consolidation ",
    "descriptionofaccountingpolicyforlicensefees": "Licensefees ",
    "warrantspolicytextblock": "Warrants ",
    "sublicenseincomepolicytextblock": "SubLicense Income ",
    "disclosureofdetailedinformationaboutestimatedusefullives": "      Fixtures and fittings    5 years      IT and equipment    3 years      Right of use asset    Economic life of contractual relationship   ",
    "disclosureofdetailedinformationaboutoperatingloss": "            Year Ended December 31,             2021 $’000      2020 $’000      2019 $’000       License fee      (1,047)      706       553       Realization bonus      855       13,503       -       Foreign exchange gain related to the realization bonus      -       (289)      -       Depreciation of Property, Plant and Equipment      8       5       5       Depreciation (Right-of-use asset)      133       86       245       Foreign exchange (gain)/losses      (1,899)      239       165    ",
    "scheduleofsegmentalreportingtabletextblock": "            UK $’000      USA $’000      Total $’000       Sublicense income      750       -       750   ",
    "disclosureofdetailedinformationaboutotherreceivablestabletextblock": "      $000         Year    ended    December 31,                     2021              2020                                               VAT Receivable              80                   82           Receivable due for options exercised              -                   191           Security deposits receivable              35                   135           Prepayments              1,186                   375                          1,301                   785        ",
    "disclosureleasedofficespacestextblock": "      Finance lease receivable         31    Dec    2021              31    Dec    2020                     $000              $000           Current              -                   152           Non-current              -                   -                          -                   152       ",
    "scheduleoffinancialliabilitiesbasedoncontractualundiscountedpaymentstabletextblock": "                2021           $000         Less    than     3 months              3    to 12     months              Total           Trade payables              2,873                   1,533                   4,406           Related party payables              1,355                   -                   1,355           Total              4,228                   1,533                   5,761       ",
    "scheduleofmeasurementofthefinancialinstrumentstextblock": "            Profit or loss and equity       December 31, 2021     Strengthening      Weakening       USD (5% movement)      90       (90)  ",
    "scheduleoftradeandotherpayablestabletextblock": "                Year    ended    December 31,           Group         2021              2020                     $000              $000           Trade payables              4,406                   3,366           Accruals              1,775                   2,224                          6,181                   5,590       ",
    "disclosureofquantitativeinformationaboutrightofuseassetstabletextblock": "      Right-of-use assets     31 Dec 2021      31 Dec 2021             $000      $000       At 1 January 2021      357       433       Depreciation      (133)      (91)      Disposal of lease      (224)      -       Exchange differences              15              -       357    ",
    "estimatedusefullives": 3,
    "estimatedusefullive": "Economic life of contractual relationship",
    "sublicenseincome": 750000,
    "otherfinanceincome": 143000,
    "licensefee": -1047000,
    "realizationbonus": 855000,
    "depreciationexpense": 8000,
    "depreciationrightofuseassets": 133000,
    "foreignexchangegainlosses": -1899000,
    "directorsremunerationexpense": 2526000,
    "wagesandsalaries": 1856000,
    "socialsecuritycontributions": 176000,
    "recruitmentfees": 242000,
    "expensefromsharebasedpaymenttransactionswithemployees": 5173000,
    "employeebenefitsexpense": 9973000,
    "researchanddevelopment": 8000,
    "corporateandadministration": 5000,
    "averagemonthlynumberofemployeesincludingdirectorsemployedbygroup": 13000,
    "directorsfees": 448000,
    "bonus": 1065000,
    "salary": 1013000,
    "sharebasedpayments": 3499000,
    "numberofshareoptionsweregrantedtodirectors": 3500000,
    "financechargeaccruedonconvertibleloannotes": 163000,
    "interestexpenseonleaseliabilities": 13000,
    "financeexpense": 176000,
    "netfinanceexpenserecognizedinstatementofcomprehensiveincome": 176000,
    "currenttaxexpenseincome": -3255000,
    "adjustmentsduetopriorperiods": -15000,
    "incometaxexpensecontinuingoperation": -3240000,
    "otherlossbeforetaxation": -26657000,
    "incometaxreconciliationlosschargedatstandardrateofcorporationtax": -5065000,
    "movementinunrecogniseddeferredtax": 1722000,
    "incometaxreconciliationexpensesnotdeductiblefortaxation": 1550000,
    "incometaxreconciliationresearchanddevelopmentclaim": -1401000,
    "incomenottaxablefortaxpurposes": -61000,
    "incometaxexpensecontinuingoperations": -3313000,
    "taxrateeffectoftaxlosses": 0.19,
    "profitlossattributabletoordinaryequityholdersofparententity": 23417000,
    "weightedaverageshares": 97932055,
    "basiclosspersharecentspershare": 23.9,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 22000,
    "propertyplantequipmentbeginningending": 77000,
    "depreciationpropertyplantandequipment": 8000,
    "depreciationipropertyplantequipmentendingbalance": 60000,
    "netbookvalueofpropertyplant": 17000,
    "valueaddedtaxreceivables": 80000,
    "securitydepositsreceivable": 35000,
    "prepayments": 1186000,
    "tradeandotherreceivables": 1301000,
    "nominalvalueannualreport": 0.03,
    "sharecapitalsharesannualreport": 194612289000,
    "sharecapitalvalueannualreport": 10794000,
    "sharepremiumannualreport": 111821000,
    "nominalvalueeliminationofsharecapital": 0.03,
    "sharecapitalshareseliminationofshare": -194612289000,
    "sharecapitalvalueeliminationofsharecapital": -10794000,
    "sharepremiumeliminationofsharecapitalin": -111821000,
    "mergerreserveeliminationofsharecapitalin": 122615000,
    "nominalvaluesharesissuedpursuanttoshareforshareexchangeandconsolidation": 0.001,
    "sharecapitalsharessharesissuedpursuantforshareexchangeandconsolidation": 97306144000,
    "sharecapitalvaluesharesissuedpursuanttoshareexchangeandconsolidation": 97000,
    "mergerreservesharesissuedpursuanttoshareforshareexchangeandconsolidation": -97000,
    "eliminationofotherreserves": -3821000,
    "nominalvaluerestated": 0.001,
    "sharecapitalsharesrestated": 97306144000,
    "sharecapitalvaluerestated": 97000,
    "mergerreserverestated": 118697000,
    "nominalvalueconversionofwarrants": 0.001,
    "sharecapitalsharesconversionofwarrants": 136854000,
    "sharepremiumconversionofwarrants": 156000,
    "nominalvalueconversionofloan": 0.001,
    "sharecapitalsharesconversionofloan": 1866907000,
    "sharecapitalvalueconversionofloan": 2000,
    "sharepremiumconversionofloan": 603000,
    "nominalvalueissuedinlieuofcashbonus": 0.001,
    "sharecapitalsharesissuedinlieuofcashbonus": 2962709000,
    "sharecapitalvalueissuedincashbonus": 3000,
    "sharepremiumissuedincashbonus": 14837000,
    "sharecapitalshares": 102272614000,
    "sharecapitalvalueat31december2021": 102000,
    "sharepremiumending": 15596000,
    "mergerreserveending": 118697000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 90,
    "numberofshareoptionsoutstanding": 22234000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 166,
    "numberofshareoptionsgranted": 5210000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 54,
    "numberofshareoptionsexercisable": 7616000,
    "grantdate": "Total",
    "expirydate": "08 October 2031",
    "shareoptionsexerciseprice": 0.72,
    "shareoptions": 22234000,
    "fairvalueoutstanding": 697000,
    "notesanddebenturesissued": 324000,
    "accruedinterest": 163000,
    "conversionofloannoteinshares": -487000,
    "tradeandotherpayables": 4406000,
    "relatedpartypayables": 1355000,
    "financialinstrumentsnet": 5761000,
    "profitorlossandequitystrengthening": 90000,
    "profitorlossandequityweakening": -90000,
    "movementpercentagestrengthening": 0.05,
    "movementpercentageweakening": 0.05,
    "tradeandotherpayablestotradesuppliers": 4406000,
    "accrualsclassifiedascurrent": 1775000,
    "tradeandothercurrentpayables": 6181000,
    "rightofuseassetbeginning": 357000,
    "rightofuseassetsdepreciation": -133000,
    "disposalofleaserightofuseassets": -224000,
    "leaseliabilitiesbeginning": 555000,
    "leaseliabilitiesinterestexpense": 13000,
    "leaseliabilitiesleasepayments": -164000,
    "disposaloflease": -394000,
    "cashsurplus": 15000000,
    "numberofsegment": 1,
    "currentaccruedexpensesandothercurrentliabilities": 900000,
    "gabrielecerronesbonusdescription": "Gabriele Cerrone’s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares ; his 2020 bonus includes a $13.2m realization bonus; his 2019 bonus covers the period June 9, 2016 to December 31, 2019",
    "postemploymentbenefitexpensedefinedcontributionplans": 24000,
    "maximumpercentageofsurrenderablelosses": 0.145,
    "termofresearchanddevelopmenttaxreliefclaims": 2,
    "taxeffectoftaxlosses": 11591000,
    "parvaluepershare": 0.001,
    "outstandingfairvaluecharges": 12339000,
    "expensefromsharebasedpaymenttransactionswithpartiesotherthanemployees": 5173000,
    "shortterminstrumentspercentage": 0.16,
    "ordinarysharesnominalvalue": 0.03,
    "decidedimpairpercentages": 2,
    "shorttermloanfacility": 72000000,
    "borrowingsinterestrate": 0.08,
    "payrollandrentcharged": 295000,
    "sharedservicesagreement": 11000,
    "netamounts": 1341000,
    "dividendspayable": 1355000,
    "servicecosts": 14000,
    "aggregateamountexpenses": 2073930,
    "treasuryshares": 3070000,
    "contributedcapitalandresources": 1400000,
    "payableamount": 1400000,
    "financialcommitmentsdescription": "(a)",
    "accruedofdiligenceobligations": 750000,
    "developmentmilestonesdescription": "(a)",
    "milestonepayments": 630,
    "entityregistrantname": "Tiziana Life Sciences Ltd",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 102272614,
    "amendmentflag": "false",
    "entitycentralindexkey": 1723069,
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityincorporationstatecountrycode": "Bermuda",
    "entityaddressaddressline1": "Finance Director",
    "entityaddressaddressline2": "55 Park Lane,",
    "entityaddresscityortown": "London",
    "entityaddresspostalzipcode": "W1K 1NA",
    "entityaddresscountry": "United Kingdom",
    "contactpersonnelname": "Keeren Shah",
    "cityareacode": 44,
    "localphonenumber": "20 7495 2379",
    "entityinteractivedatacurrent": "No",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1401,
    "auditorname": "MazarsLLP",
    "auditorlocation": "London,England",
    "documentregistrationstatement": "false",
    "entityfilenumber": "000-00000"
  },
  {
    "date": "2020-12-31",
    "symbol": "TLSA",
    "period": "FY",
    "cashandcashequivalents": 65824000,
    "prepaymentsandotherreceivablescurrent": 785000,
    "financeleasereceivables": 152000,
    "taxationreceivable": 3047000,
    "amountsreceivablerelatedpartytransactions": 368000,
    "currentassets": 70176000,
    "propertyplantandequipment": 3000,
    "noncurrentfinanceleasereceivables": 120000,
    "rightofuseassets": 357000,
    "noncurrentassets": 480000,
    "assets": 70656000,
    "accountspayableandaccruedexpensescurrent": 5590000,
    "currentleaseliabilities": 265000,
    "amountspayablerelatedpartytransactions": 4000,
    "otherliabilities": 85000,
    "currentliabilities": 7980000,
    "noncurrentleaseliabilities": 290000,
    "liabilities": 8270000,
    "issuedcapital": 10794000,
    "sharepremium": 111821000,
    "reserveofsharebasedpayments": 8624000,
    "sharebasedpaymentreservewarrants": 697000,
    "sharestobeissuedreserve": 13503000,
    "otherreserves": -46171000,
    "reserveofexchangedifferencesontranslation": 5414000,
    "capitalredemptionreserve": 42350000,
    "retainedearnings": -84646000,
    "equity": 42350000,
    "equityandliabilities": 70656000,
    "issuanceofsharecapital": 194612289,
    "sharecapitaloutstanding": 194612289,
    "researchanddevelopmentexpense": 5993000,
    "otheroperatingincomeexpense": -11203000,
    "realisationbonus": 13214000,
    "impairmentloss": 279000,
    "distributioncosts": -2663000,
    "totaloperatingexpenses": -28026000,
    "profitlossfromoperatingactivities": -28026000,
    "financeincomecost": -312000,
    "profitlossbeforetax": -28338000,
    "incometaxexpensecontinuingoperations": -2207000,
    "profitloss": -26131000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 3474000,
    "comprehensiveincome": -22657000,
    "basicearningslosspershare": -15.46,
    "numberofsharesoutstanding": 194612289,
    "issueofequity": 71157000,
    "issueofsharecapitalshares": 43979245,
    "issueofsharecapital": 466000,
    "issueofsharecapitalinlieuoffeesinshares": 281250,
    "issueofsharecapitalwarrants": 3364000,
    "issueofsharecapitalwarrantsinshares": 6365428,
    "issueofsharecapitalloanconversion": -2304000,
    "issueofsharecapitalloanconversioninshares": 4406125,
    "issueofsharecapitaloptions": 939000,
    "convertibleloannoteissued": 163000,
    "optionsforfeitedcancelled": -35000,
    "exerciseofoptions": 1529000,
    "exerciseofoptionsinshares": 2925725,
    "increasedecreasethroughexerciseofwarrantsequity": 810000,
    "sharestobeissuedinlieuofcashrealizationbonus": 13503000,
    "reductioninsharepremium": 5461000,
    "capitaldistributions": -4403000,
    "increasedecreasethroughconvertibleloannoteinterest": 272000,
    "increasedecreasethroughexerciseofoptions": 5105000,
    "sharebasedpaymentwarrants": 26000,
    "increasedecreasethroughtransactionswithowners": 91101000,
    "totaltransactionswithownersshares": 57957773,
    "profitloss1": -26131000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation1": 3474000,
    "comprehensiveincome1": -22657000,
    "adjustmentsforinterestexpense": 272000,
    "sharesissuedinlieuoffees": 466000,
    "adjustmentsforforfeitureofoptions": -5070000,
    "adjustmentsforsharebasedpaymentswarrants": 26000,
    "bonustobesettledinequity": 13503000,
    "netincreaseinrelatedpartyreceivables": 31000,
    "netincreaseinrelatedpartypayables": 1145000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -437000,
    "adjustmentsforincreasedecreaseinotherliabilities": -972000,
    "adjustmentsfordepreciationexpense": 5000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -237000,
    "depreciationofrightofuseasset": 86000,
    "impairmentcharges": 296000,
    "capitaldistribution": 2663000,
    "cashflowsfromusedinoperatingactivities": -11335000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3000,
    "purchaseofactd": 120000,
    "cashflowsfromusedininvestingactivities": -123000,
    "fundraisingcost": 71157000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 163000,
    "proceedsfromissuanceofwarrant": 3364000,
    "proceedsfromissuanceofoptions": 939000,
    "repaymentofleasingliabilities": -277000,
    "cashflowsfromusedinfinancingactivities": 75346000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 63888000,
    "effectofexchangeratechangesoncashandcashequivalents": 1736000,
    "estimatedusefullives": "P3Y",
    "estimatedusefullive": "Economic life of contractual relationship",
    "licensefee": 706000,
    "realizationbonus": 13503000,
    "operatingloss": -289000,
    "depreciationexpense": 5000,
    "depreciationrightofuseassets": 86000,
    "foreignexchangegainlosses": 239000,
    "directorsremunerationexpense": 14666000,
    "wagesandsalaries": 1058000,
    "socialsecuritycontributions": 194000,
    "recruitmentfees": 17000,
    "expensefromsharebasedpaymenttransactionswithemployees": 5105000,
    "employeebenefitsexpense": 21040000,
    "researchanddevelopment": 3000,
    "corporateandadministration": 8000,
    "averagemonthlynumberofemployeesincludingdirectorsemployedbygroup": 11000,
    "directorsfees": 170000,
    "bonus": 210000,
    "salary": 600000,
    "sharebasedpayments": 2069000,
    "numberofshareoptionsweregrantedtodirectors": 2300000,
    "financeincomereceivedonnetinvestmentinlease": -8000,
    "financeincome": 8000,
    "financechargeaccruedonconvertibleloannotes": 303000,
    "interestexpenseonleaseliabilities": 17000,
    "financeexpense": 320000,
    "netfinanceexpenserecognizedinstatementofcomprehensiveincome": 312000,
    "currenttaxexpenseincome": -1546000,
    "adjustmentsduetopriorperiods": -661000,
    "incometaxexpensecontinuingoperation": -2207000,
    "otherlossbeforetaxation": -28337000,
    "incometaxreconciliationlosschargedatstandardrateofcorporationtax": -5384000,
    "movementinunrecogniseddeferredtax": 1316000,
    "incometaxreconciliationexpensesnotdeductiblefortaxation": 4986000,
    "incometaxreconciliationresearchanddevelopmentclaim": -665000,
    "incomenottaxablefortaxpurposes": -1741000,
    "increasedecreasethroughforeignexchangeandothermovementsfinancialassets": -58000,
    "taxrateeffectoftaxlosses": 0.19,
    "profitlossattributabletoordinaryequityholdersofparententity": 26131000,
    "weightedaverageshares": 169065390,
    "basiclosspersharecentspershare": 15.46,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 1000,
    "propertyplantequipmentbeginningending": 55000,
    "depreciationpropertyplantandequipment": 5000,
    "depreciationipropertyplantequipmentendingbalance": 52000,
    "netbookvalueofpropertyplant": 3000,
    "valueaddedtaxreceivables": 82000,
    "receivabledueforoptionsexercised": 191000,
    "securitydepositsreceivable": 135000,
    "prepayments": 375000,
    "tradeandotherreceivables": 785000,
    "financeleasereceivablecurrent": 152000,
    "financeleasereceivable": 152000,
    "undiscountedleasepaymentsreceivable": 152000,
    "undiscountedleasepaymentsreceivabletotal": 152000,
    "financeleasesreceivable": 292000,
    "subleasesincome": -152000,
    "exchangeratedifferences": 12000,
    "financeleasereceivabletotal": 152000,
    "nameofsubsidiary": "Stemprinter Sciences Ltd",
    "principalactivityinsubsidiaries": "Specialist medical practice activities",
    "principalplaceofbusinessofsubsidiary": "9th Floor, 107 Cheapside, London, UK EC2V 6DN",
    "percentageofinvestmentsinsubsidiaries": 1,
    "countryofincorporation": "England & Wales",
    "numberofsharesissued": 194612289,
    "sharecapitalissued": 10794000,
    "numberofsharesissuedforcashinshares": 43979245,
    "sharesissuedforcash": 1667000,
    "issuedinlieuofconsultancyfees": 281250,
    "issuedinlieuofconsultancyfeesvalue": 11000,
    "conversionofwarrants": 6365428,
    "conversionofwarrantsvalue": 239000,
    "conversionofloan": 4406125,
    "conversionofloanvalue": 165000,
    "exerciseofoption": 2925725,
    "exerciseofoptionsvalue": 113000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 67,
    "numberofshareoptionsoutstanding": 17024000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 111,
    "numberofshareoptionsgranted": 3870000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 52,
    "numberofshareoptionsforfeited": -300000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": -25,
    "numberofoptionsexercised": -2925,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 65,
    "numberofshareoptionsexercisable": 6249000,
    "grantdate": "Total",
    "expirydate": "24 August 2030",
    "shareoptionsexerciseprice": 1.98,
    "shareoptions": 17024000,
    "sharebasedpaymentreservewarrant": 697000,
    "sharebasedpaymentwarrantsgranted": 324000,
    "sharebasedpaymentwarrantstransfertosharepremiumonexerciseofwarrants": -2046000,
    "notesanddebenturesissued": 313000,
    "accruedinterest": 11000,
    "borrowings": 324000,
    "convertibleloannotesissued": 2175000,
    "fairvalueofwarrantsissuedtonoteholders": -661000,
    "totalconvertiblenotesissued": 1514000,
    "accruedinterests": 348000,
    "lessconvertibleloannoteconversion": -2523000,
    "exerciseofwarrant": 661000,
    "tradeandotherpayables": 3366000,
    "relatedpartypayables": 2040000,
    "financialinstrumentsnet": 5406000,
    "tradeandotherpayablestotradesuppliers": 3366000,
    "accrualsclassifiedascurrent": 2224000,
    "tradeandothercurrentpayables": 5590000,
    "rightofuseassetbeginning": 433000,
    "rightofuseassetsdepreciation": -91000,
    "rightofuseassetstotal": 342000,
    "leaseliabilitiesbeginning": 820000,
    "leaseliabilitiesinterestexpense": 18000,
    "leaseliabilitiesleasepayments": -321000,
    "exchangedifferences": -38000,
    "leaseliabilitiestotal": 555000,
    "totalleaseliablilities": 555000,
    "leasepayments": 583000,
    "financecharges": -29000,
    "netpresentvalues": 554000,
    "numberofsegment": 1,
    "consultancyfees": 2073930,
    "fairvalueofaccount": 283246,
    "numberofsharesissuedandfullypaid": 3070000,
    "contributedcapitalandresources": 1400000,
    "cash": 1400000,
    "parvaluepershare": 0.03,
    "cancelledsharepremiuim": 5461000,
    "notesanddebentureissued": 1400000,
    "exercisedsharesoptions": 2319225,
    "intrinsicgain": 4000000,
    "postemploymentbenefitexpensedefinedcontributionplans": 10000,
    "maximumpercentageofsurrenderablelosses": 0.145,
    "termofresearchanddevelopmenttaxreliefclaims": "P2Y",
    "taxeffectoftaxlosses": 6182,
    "undiscountedleaseyears": "P5Y",
    "discountfactorcharge": 6000,
    "incomefromsubleasingrightofuseassets": 152000,
    "companyterm": "2 years",
    "impirementcharge": 278000,
    "sharesofoptionsexercised": 2925725,
    "outstandingfairvaluedescription": "The total outstanding fair value charge of the share option instruments is deemed to be approximately $7,046k (2019: $5,237k).",
    "expectedtermofawards": "P4Y",
    "sharebasedpaymentcharge": 29000,
    "convertibleequityinstrumentdescription": "the Company decided to raise convertible equity finance from supportive existing shareholders. $1,850,000 was raised from the issuance of Convertible Loan Notes. The Loan Notes are short term instruments and carry a coupon of 16% per annum and are convertible (together with all accrued interest) into ordinary shares of nominal value &#xa3;0.03 each in the capital of the Company at a conversion price of 42p, they are not convertible into cash.",
    "warrantsexercisedperiod": "P5Y",
    "reductionofissuedcapital": 31000000,
    "shorttermloanfacility": 72000000,
    "borrowingsinterestrate": 0.08,
    "payrollandrentcharged": 348000,
    "convertibledebtinstrumentoutstanding": 1346000,
    "cashpayable": 1342000,
    "optionexerciseprice": 191000000,
    "cashoutflow": 206703000,
    "financialcommitmentsdescription": "(a) $100,000 upon initiation, first patient dosed, or FPD, of the first Phase 3 registration trial in thymic carcinoma. (b) $4,000,000 upon FPD of the first Phase 3 registration trial in HCC. (c) $6,000,000 upon FPD of the first Phase 3 registration trial in breast cancer. (d) Upon the first NDA equivalent in: thymic carcinoma, $900,000; HCC, $9,000,000; breast cancer, $15,000,000.",
    "accruedofdiligenceobligations": 1500000,
    "milestonepayments": 630000,
    "entityregistrantname": "Tiziana Life Sciences plc",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 194612289,
    "amendmentflag": "false",
    "entitycentralindexkey": 1723069,
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documentshellcompanyreport": "false",
    "documenttransitionreport": "false",
    "entityincorporationstatecountrycode": "X0",
    "entityinteractivedatacurrent": "No"
  },
  {
    "date": "2019-12-31",
    "symbol": "TLSA",
    "period": "FY",
    "entityregistrantname": "Tiziana Life Sciences plc",
    "entitycentralindexkey": 1723069,
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documenttype": "20-F",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "Yes",
    "entitycurrentreportingstatus": "No",
    "entityinteractivedatacurrent": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 136654516,
    "entityincorporationstatecountrycode": "X0",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cashandcashequivalents": 200000,
    "prepaymentsandotherreceivablescurrent": 165000,
    "financeleasereceivables": 143000,
    "taxationreceivable": 675000,
    "amountsreceivablerelatedpartytransactions": 322000,
    "currentassets": 1505000,
    "propertyplantandequipment": 3000,
    "noncurrentfinanceleasereceivables": 149000,
    "rightofuseassets": 433000,
    "othernoncurrentfinancialassets": 285000,
    "noncurrentassets": 873000,
    "assets": 2378000,
    "accountspayableandaccruedexpensescurrent": 6396000,
    "currentleaseliabilities": 279000,
    "amountspayablerelatedpartytransactions": 594000,
    "otherliabilities": 82000,
    "currentliabilities": 7351000,
    "noncurrentleaseliabilities": 541000,
    "liabilities": 7892000,
    "issuedcapital": 8599000,
    "sharepremium": 39931000,
    "reserveofsharebasedpayments": 5163000,
    "sharebasedpaymentreservewarrants": 2419000,
    "reserveofconvertibleloannote": 1357000,
    "otherreserves": -46171000,
    "reserveofexchangedifferencesontranslation": 1940000,
    "capitalredemptionreserve": 41292000,
    "retainedearnings": -60044000,
    "equity": 41292000,
    "equityandliabilities": 2378000,
    "issuanceofsharecapital": 136654516,
    "sharecapitaloutstanding": 136654516,
    "researchanddevelopmentexpense": 3714000,
    "otheroperatingincomeexpense": -6207000,
    "totaloperatingexpenses": -9921000,
    "profitlossfromoperatingactivities": -9921000,
    "financeincomecost": -91000,
    "profitlossbeforetax": -10012000,
    "incometaxexpensecontinuingoperations": -689000,
    "profitloss": -9323000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -27000,
    "comprehensiveincome": -9350000,
    "basicanddilutedearningslosspershare": -0.07,
    "numberofsharesoutstanding": 136654516,
    "issueofequity": 99000,
    "issueofsharecapitalshares": 190698,
    "convertibledebtissued": 1850000,
    "increasedecreasethroughconvertibleloannoteinterest": 52000,
    "increasedecreasethroughexerciseofoptions": 1309000,
    "increasedecreasethroughexerciseofwarrantsequity": -545000,
    "increasedecreasethroughtransactionswithowners": 1357000,
    "totaltransactionswithownersshares": 190698,
    "profitloss1": -9323000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation1": -27000,
    "comprehensiveincome1": -27000,
    "adjustmentsforinterestexpense": 50000,
    "sharesissuedinlieuoffees": 105000,
    "adjustmentsforsharebasedpayments": 1266000,
    "netincreaseinrelatedpartyreceivables": -287000,
    "netincreaseinrelatedpartypayables": 436000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 159000,
    "adjustmentsforincreasedecreaseinotherliabilities": -23000,
    "adjustmentsfordepreciationexpense": 5000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 165000,
    "depreciationofrightofuseasset": 248000,
    "profitslossesondisposalofinvestmentsandchangesinvalueofinvestments": 71000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 1021000,
    "cashflowsfromusedinoperatingactivities": -6796000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 4000,
    "cashflowsfromusedininvestingactivities": -4000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 1880000,
    "repaymentofleasingliabilities": -200000,
    "cashflowsfromusedinfinancingactivities": 1680000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -5120000,
    "effectofexchangeratechangesoncashandcashequivalents": 16000,
    "estimatedusefullives": "P5Y",
    "parvaluepershare": 0.03,
    "numberofsegment": 1,
    "leaseliabilities": 1098000,
    "operatingleasecommitmentsdisclosedunderias17": 1142000,
    "remainingleasecommitmentsdiscountedusinggroupsincrementalborrowingrateasatdateofinitialapplication": 1098000,
    "propertiesofrightofuseassets": 433000,
    "licensefee": 553000,
    "depreciationexpense": 5000,
    "depreciationrightofuseassets": 245000,
    "operatingloss": 967000,
    "directorsremunerationexpense": 1145000,
    "wagesandsalaries": 696000,
    "socialsecuritycontributions": 609000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1266000,
    "employeebenefitsexpense": 3716000,
    "researchanddevelopment": 5000,
    "corporateandadministration": 4000,
    "averagemonthlynumberofemployeesincludingdirectorsemployedbygroup": 9000,
    "directorsfees": 102000,
    "bonus": 210000,
    "salary": 600000,
    "postemploymentbenefitexpensedefinedcontributionplans": 15000,
    "financeincomereceivedonnetinvestmentinlease": 1000,
    "financeincome": 1000,
    "financechargeaccruedonconvertibleloannotes": 61000,
    "interestexpenseonleaseliabilities": 31000,
    "financeexpense": 92000,
    "financecosts": 92000,
    "currenttaxexpenseincome": -661000,
    "adjustmentsduetopriorperiods": -28000,
    "incometaxreconciliationlosschargedatstandardrateofcorporationtax": -1903000,
    "movementinunrecogniseddeferredtax": -241000,
    "incometaxreconciliationexpensesnotdeductiblefortaxation": 1727000,
    "adjustmentsforcurrenttaxofpriorperiod": -28000,
    "incometaxreconciliationresearchanddevelopmentclaim": -285000,
    "increasedecreasethroughforeignexchangeandothermovementsfinancialassets": -689000,
    "taxrateeffectoftaxlosses": 0.2149,
    "maximumpercentageofsurrenderablelosses": 0.145,
    "termofresearchanddevelopmenttaxreliefclaims": "P2Y",
    "taxeffectoftaxlosses": 3517000,
    "profitlossattributabletoordinaryequityholdersofparententity": -9323000,
    "weightedaverageshares": 136482627,
    "basicearningslosspershare": -6.83,
    "propertyplantequipmentcost": 35000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 4000,
    "depreciationimpairmentpropertyplantequipment": 32000,
    "depreciationpropertyplantandequipment": 2000,
    "otherreceivables": 134000,
    "receivablesfromtaxesotherthanincometax": 676000,
    "prepayments": 28000,
    "tradeandotherreceivables": 1162000,
    "financeleasereceivablecurrent": 142000,
    "financeleasereceivablenoncurrent": 149000,
    "financeleasereceivable": 292000,
    "undiscountedleasepaymentsreceivable": 149000,
    "undiscountedleasepaymentsreceivabletotal": 149000,
    "financeleasesreceivable": 327000,
    "subleasesincome": -36000,
    "financeleasereceivabletotal": 292000,
    "nameofsubsidiary": "Longevia Genomics SRL",
    "principalactivityinsubsidiaries": "Biotech Discovery Company",
    "principalplaceofbusinessofsubsidiary": "Via Constantinpoli 42 09100-Cagliari (CA)",
    "percentageofinvestmentsinsubsidiaries": 1,
    "countryofincorporation": "Italy",
    "numberofsharesissued": 136654516,
    "issuedinlieuofconsultancyfees": 190698,
    "sharecapitalissued": 8599000,
    "issuedinlieuofconsultancyfeesvalue": 7000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 113,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": -152,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 67,
    "numberofshareoptionsoutstanding": 16379000,
    "numberofshareoptionsforfeited": -2238000,
    "numberofshareoptionsexercisable": 5521000,
    "sharepriceshareoptionsgranted": 1.041,
    "shareoptionsexerciseprice": 1.041,
    "vestingperiodshareoptionsgranted": "Yr1, Yr 2, Yr 3, Yr4",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0103,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.6,
    "optionlifeshareoptionsgranted": "P10Y0M0D",
    "weightedaverageshareprice2019": 1.041,
    "weightedaveragesharepriceshareoptionsgranted2019": 0.484,
    "fairvalueshareoptioninstruments": 5011000,
    "expectedtermofawards": "P15Y",
    "notesanddebenturesissued": 302000,
    "accruedinterest": 11000,
    "borrowings": 313000,
    "convertibleloannotesissued": 1850000,
    "fairvalueofwarrantsissuedtonoteholders": -545000,
    "totalconvertiblenotesissued": 1305000,
    "accruedinterests": 52000,
    "totalconvertblenotesandwarrantsissued": 1357000,
    "reductionofissuedcapital": 31100000,
    "tradeandotherpayables": 3612000,
    "relatedpartypayables": 330000,
    "financialinstrumentsnet": 3942000,
    "tradeandothercurrentpayablestotradesuppliers": 4191000,
    "accrualsclassifiedascurrent": 2206000,
    "tradeandothercurrentpayables": 6397000,
    "rightofuseasset": 433000,
    "rightofuseassetsdepreciation": -256000,
    "rightofuseassetsfinanceleasereceivable": -328000,
    "rightofuseassetslossondisposal": -74000,
    "rightofuseassetsforeignexchangemovements": -6000,
    "leaseliability": 820000,
    "leaseliabilitiesinterestexpense": 30000,
    "leaseliabilitiesleasepayments": -309000,
    "totalleaseliablilities": 820000,
    "leasepayments": 295000,
    "financecharges": -15000,
    "netpresentvalues": 280000,
    "cashoutflow": 206703000,
    "payrollandrentcharged": 320000,
    "shorttermloanfacility": 527000,
    "interestpayablepercentage": 0.2,
    "tradeandotherpayablestorelatedparties": 264000,
    "interestaccruedonloan": 40000,
    "convertibledebtinstrumentoutstanding": 332000
  }
]